The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC).
David J. Watkins
No relevant relationships to disclose
Mark Ayers
Employment or Leadership Position - Merck
David Cunningham
Consultant or Advisory Role - Roche (U)
Research Funding - Amgen; AstraZeneca; Roche
Expert Testimony - Amgen (U)
Josep Tabernero
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Sabine Tejpar
No relevant relationships to disclose
Tae-You Kim
Research Funding - Merck
Tae Won Kim
Research Funding - Merck
Sun Young Kim
Research Funding - Merck
Jae Kyung Roh
Research Funding - Merck
Philip James Beale
Research Funding - Merck
Young Suk Park
Research Funding - Merck
Tormod Kyrre Guren
Research Funding - Merck
Andrey Loboda
Employment or Leadership Position - Merck
Michael Nebozhyn
Employment or Leadership Position - Merck
Robin Mogg
Employment or Leadership Position - Merck
Jared Lunceford
Employment or Leadership Position - Merck
Emmett V. Schmidt
Employment or Leadership Position - Merck
Holly M. Brown
Employment or Leadership Position - Merck
Stock Ownership - Merck
Sriram Sathyanarayanan
Employment or Leadership Position - Merck
David J. Mauro
Employment or Leadership Position - Merck